Tag: GLP-1

Research Context

The synthesis packet contains 12 PubMed-indexed sources: eight primary human studies and four reviews; no preclinical sources. Conclusions should remain anchored to the specific populations, endpoints, and formulations explicitly studied. Review literature can frame context but does not substitute for primary human outcome data.

Direct Answer

Published human randomized trials in this packet most robustly report weight-management outcomes primarily in adults with overweight or obesity without diabetes, using both subcutaneous and oral formulations [pubmed:35015037][pubmed:37385278][pubmed:38330988]. Additional human research addresses functional capacity (walking outcomes) in people with symptomatic peripheral artery disease and type 2 diabetes [pubmed:40169145]. Cardiovascular outcomes and metabolic dysfunction–associated steatohepatitis (MASH) are represented here only by trial design/baseline publications, without reported outcomes [pubmed:36945734][pubmed:39412509]. Systematic reviews synthesize efficacy in obesity without diabetes; a safety-focused review addresses semaglutide more broadly and should not be over-narrowed to obesity-only contexts [pubmed:36578889][pubmed:38679221][pubmed:34942372][pubmed:34305810].

Human Clinical Evidence

• Weight management in adults (primarily without diabetes)
• STEP 8: Weekly subcutaneous semaglutide versus daily liraglutide; primary outcomes centered on body-weight change in adults with overweight or obesity without diabetes [pubmed:35015037].
• OASIS 1: Oral semaglutide 50 mg once daily versus placebo; weight outcomes in adults with overweight or obesity (the title does not specify diabetes status) [pubmed:37385278].
• STEP 7: Once-weekly semaglutide 2.4 mg versus placebo; weight outcomes in a predominantly East Asian population with overweight or obesity [pubmed:38330988].

• Functional capacity in peripheral artery disease with type 2 diabetes
• STRIDE (phase 3b): Double-blind, randomized, placebo-controlled trial evaluating walking capacity endpoints in people with symptomatic peripheral artery disease and type 2 diabetes [pubmed:40169145].

• Cardiovascular outcomes (design/baseline only in this packet)
• SOUL: Design and baseline characteristics for a randomized cardiovascular outcomes trial of oral semaglutide in people with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease; no outcomes are reported in the materials provided here [pubmed:36945734].

• MASH (design/baseline only in this packet)
• ESSENCE (phase 3): Baseline characteristics and trial design evaluating semaglutide 2.4 mg in participants with MASH; no outcomes are reported in the materials provided here [pubmed:39412509].

• Comparator and combination contexts (do not imply monotherapy outcomes)
• Tirzepatide comparator trial (phase 1): Multicenter, randomized, double-blind study comparing tirzepatide with placebo or semaglutide on islet function and insulin sensitivity in adults with type 2 diabetes; this context does not establish semaglutide monotherapy efficacy beyond its role as a comparator [pubmed:35468322].
• Cagrilintide–semaglutide combination: Study in adults with overweight or obesity and type 2 diabetes; as a combination therapy, it does not isolate semaglutide monotherapy effects [pubmed:40544432].

Outcome evidence is strongest for weight-management trials primarily in adults without diabetes. Cardiovascular and MASH questions are represented here by design/baseline papers only and should not be interpreted as established clinical outcomes within this packet.

Review Literature

• Systematic review and meta-analysis on efficacy and safety for weight loss in obesity without diabetes [pubmed:36578889].
• Systematic review and meta-analysis on long-term efficacy and safety of once-weekly semaglutide for weight loss in patients without diabetes across randomized controlled trials [pubmed:38679221].
• Review on semaglutide for the treatment of obesity [pubmed:34942372].
• Safety-focused review addressing semaglutide broadly (not limited to obesity without diabetes) [pubmed:34305810].

These reviews contextualize mechanisms, efficacy, and safety but remain limited by the included primary RCTs and do not extend findings to unstudied populations, endpoints, or formulations beyond those tested.

Preclinical and Mechanistic Evidence

• No preclinical or purely mechanistic sources are included in the packet.

What Is Not Established

• Cardiovascular outcomes and MASH efficacy: Only trial designs/baseline characteristics are included (SOUL, ESSENCE); no outcome data are provided here and efficacy should not be inferred.
• Generalized dosing and safety extrapolation beyond the studied contexts.
• Anti-aging or broad peptide claims unsupported by direct human outcomes in this packet.
• Cross-formulation or cross-population generalizations not tested in the cited studies.

References

• [pubmed:35015037] Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/35015037/
• [pubmed:37385278] Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. https://pubmed.ncbi.nlm.nih.gov/37385278/
• [pubmed:38330988] Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial. https://pubmed.ncbi.nlm.nih.gov/38330988/
• [pubmed:40169145] Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. https://pubmed.ncbi.nlm.nih.gov/40169145/
• [pubmed:36945734] Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial. https://pubmed.ncbi.nlm.nih.gov/36945734/
• [pubmed:39412509] Semaglutide 2.4 mg in Participants With Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial. https://pubmed.ncbi.nlm.nih.gov/39412509/
• [pubmed:35468322] Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. https://pubmed.ncbi.nlm.nih.gov/35468322/
• [pubmed:40544432] Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. https://pubmed.ncbi.nlm.nih.gov/40544432/
• [pubmed:36578889] Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis. https://pubmed.ncbi.nlm.nih.gov/36578889/
• [pubmed:38679221] Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. https://pubmed.ncbi.nlm.nih.gov/38679221/
• [pubmed:34942372] Semaglutide for the treatment of obesity. https://pubmed.ncbi.nlm.nih.gov/34942372/
• [pubmed:34305810] Safety of Semaglutide. https://pubmed.ncbi.nlm.nih.gov/34305810/

Research-use-only catalog access

KRL product pages are gated and require age and research-use-only acknowledgement before prices, cart, or checkout are available.